(Q38120066)

29 August 2017

title

The mechanism of action, pharmacokinetics, and clinical efficacy of carfilzomib for the treatment of multiple myeloma (English)

1 reference

29 August 2017

1 reference

5

Antonio Palumbo

1 reference

29 August 2017

Chiara Pautasso

1

1 reference

29 August 2017

Sara Bringhen

series ordinal

2

1 reference

29 August 2017

Chiara Cerrato

series ordinal

3

1 reference

29 August 2017

Valeria Magarotto

series ordinal

4

1 reference

29 August 2017

language of work or name

English

0 references

publication date

9 July 2013

1 reference

Expert Opinion on Drug Metabolism & Toxicology

29 August 2017

published in

1 reference

29 August 2017

volume

9

1 reference

29 August 2017

issue

10

1 reference

29 August 2017

page(s)

1371-1379

1 reference

How to treat elderly patients with multiple myeloma: combination of therapy or sequencing.

29 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2013.817556

Clinical pharmacokinetics, metabolism, and drug-drug interaction of carfilzomib.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2013.817556

Epoxomicin, a new antitumor agent of microbial origin

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2013.817556

Epoxomicin, a potent and selective proteasome inhibitor, exhibits in vivo antiinflammatory activity

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2013.817556

Total synthesis of the potent proteasome inhibitor epoxomicin: a useful tool for understanding proteasome biology.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2013.817556

Antitumor activity of PR-171, a novel irreversible inhibitor of the proteasome

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2013.817556

The epoxyketone-based proteasome inhibitors carfilzomib and orally bioavailable oprozomib have anti-resorptive and bone-anabolic activity in addition to anti-myeloma effects.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2013.817556

Pharmacokinetics, pharmacodynamics, metabolism, distribution, and excretion of carfilzomib in rats.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2013.817556

A phase 1 dose escalation study of the safety and pharmacokinetics of the novel proteasome inhibitor carfilzomib (PR-171) in patients with hematologic malignancies

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2013.817556

A phase I single-agent study of twice-weekly consecutive-day dosing of the proteasome inhibitor carfilzomib in patients with relapsed or refractory multiple myeloma or lymphoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2013.817556

A phase 1/2 study of carfilzomib in combination with lenalidomide and low-dose dexamethasone as a frontline treatment for multiple myeloma

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2013.817556

A phase 2 study of single-agent carfilzomib (PX-171-003-A1) in patients with relapsed and refractory multiple myeloma

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2013.817556

An open-label, single-arm, phase 2 (PX-171-004) study of single-agent carfilzomib in bortezomib-naive patients with relapsed and/or refractory multiple myeloma

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2013.817556

An open-label, single-arm, phase 2 study of single-agent carfilzomib in patients with relapsed and/or refractory multiple myeloma who have been previously treated with bortezomib

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2013.817556

10.1517/17425255.2013.817556

21 January 2018

Identifiers

DOI

1 reference

29 August 2017

1 reference